Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

NCT03178552 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03178552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03178552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
September 22, 2017
Completion date
June 30, 2027
Enrollment
1,000 (estimated)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer